$94.38
+2.61
(+2.84%)
As of Oct 15, 2026, 9:56 PM EDT
Price history
Zimmer Biomet (ZBH) is trading up at $94.38 (+2.84%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Zimmer Biomet revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $7.68B | $7.82B | $7.93B | $7.98B | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B |
| Growth (year over year) | +28.1% | +1.8% | +1.4% | +0.6% | −23.2% | +11.4% | +1.6% | +6.5% | +3.8% | +7.2% |
| Gross profit | $5.30B | $5.69B | $5.66B | $5.73B | $4.30B | $4.87B | $4.92B | $5.31B | $5.49B | $5.74B |
| Gross margin | 69.0% | 72.7% | 71.4% | 71.8% | 70.2% | 71.3% | 70.9% | 71.8% | 71.5% | 69.7% |
| Operating income | $821.1M | $799.3M | $33.8M | $1.14B | $83.1M | $860.3M | $696.3M | $1.28B | $1.29B | $1.10B |
| Operating margin | 10.7% | 10.2% | 0.4% | 14.3% | 1.4% | 12.6% | 10.0% | 17.3% | 16.7% | 13.3% |
| Net income | $305.9M | $1.81B | −$379.2M | $1.13B | −$138.9M | $401.6M | $231.4M | $1.02B | $903.8M | $705.1M |
| Net margin | 4.0% | 23.2% | −4.8% | 14.2% | −2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
| EPS (diluted) | $1.51 | $8.90 | −$1.86 | $5.47 | −$0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Balance sheet | ||||||||||
| Cash and equivalents | $634.1M | $524.4M | $542.8M | $617.9M | $802.1M | $378.1M | $375.7M | $415.8M | $525.5M | $591.9M |
| Total assets | $26.7B | $26.0B | $24.1B | $24.6B | $24.4B | $23.5B | $21.1B | $21.5B | $21.4B | $23.1B |
| Total liabilities | $17.0B | $14.3B | $12.9B | $12.2B | $12.2B | $10.8B | $9.04B | $9.01B | $8.89B | $10.4B |
| Long-term debt | $10.7B | $8.92B | $8.41B | $6.72B | $7.63B | $5.46B | $5.15B | $4.87B | $5.34B | $6.93B |
| Shareholders' equity | $9.67B | $11.7B | $11.3B | $12.4B | $12.2B | $12.7B | $12.0B | $12.5B | $12.5B | $12.7B |
| Cash flow | ||||||||||
| Operating cash flow | $1.63B | $1.58B | $1.75B | $1.59B | $1.20B | $1.50B | $1.36B | $1.58B | $1.50B | $1.70B |
| Capital expenditure | $184.7M | $156.0M | $162.7M | $207.1M | $111.9M | $143.6M | $187.9M | $291.1M | $203.8M | $224.5M |
| Free cash flow | $1.45B | $1.43B | $1.58B | $1.38B | $1.09B | $1.36B | $1.17B | $1.29B | $1.30B | $1.47B |
| Dividends paid | $188.4M | $193.6M | $195.2M | $196.7M | $198.5M | $200.1M | $201.2M | $200.9M | $196.0M | $190.3M |
| Share buybacks | $415.5M | — | — | — | — | — | $126.4M | $692.2M | $868.0M | $487.0M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.82B | $2.02B | $1.91B | $2.08B | $2.00B | $2.24B | $2.09B | $2.18B |
| Growth (year over year) | +4.0% | +4.3% | +1.1% | +7.0% | +9.7% | +10.9% | +9.3% | +4.8% |
| Gross profit | $1.29B | $1.44B | $1.36B | $1.49B | $1.44B | $1.45B | $1.51B | $1.54B |
| Gross margin | 70.5% | 71.0% | 71.2% | 71.5% | 72.1% | 64.7% | 72.4% | 70.8% |
| Operating income | $279.5M | $389.0M | $292.3M | $300.0M | $351.3M | $154.5M | $373.2M | $326.1M |
| Operating margin | 15.3% | 19.2% | 15.3% | 14.4% | 17.6% | 6.9% | 17.9% | 15.0% |
| Net income | $249.1M | $239.5M | $182.0M | $152.8M | $230.9M | $139.4M | $238.1M | $198.3M |
| Net margin | 13.7% | 11.8% | 9.5% | 7.4% | 11.5% | 6.2% | 11.4% | 9.1% |
| EPS (diluted) | $1.23 | $1.18 | $0.91 | $0.77 | $1.16 | $0.71 | $1.22 | $1.03 |
| Balance sheet | ||||||||
| Cash and equivalents | $569.0M | $525.5M | $1.38B | $556.9M | $1.29B | $591.9M | $424.2M | $410.0M |
| Total assets | $21.7B | $21.4B | $22.2B | $22.9B | $23.5B | $23.1B | $22.7B | $22.8B |
| Total liabilities | $9.34B | $8.89B | $9.78B | $10.3B | $10.7B | $10.4B | $10.0B | $10.2B |
| Long-term debt | $4.74B | $5.34B | $6.58B | $6.75B | $7.51B | $6.93B | $6.30B | $6.28B |
| Shareholders' equity | $12.4B | $12.5B | $12.4B | $12.5B | $12.8B | $12.7B | $12.7B | $12.6B |
| Cash flow | ||||||||
| Operating cash flow | $395.7M | $506.3M | $382.8M | $378.2M | $418.7M | $517.4M | $359.4M | $447.8M |
| Capital expenditure | $44.5M | $51.5M | $44.6M | $50.1M | $55.0M | $74.8M | $36.3M | $54.2M |
| Free cash flow | $351.2M | $454.8M | $338.2M | $328.1M | $363.7M | $442.6M | $323.1M | $393.6M |
| Dividends paid | $49.2M | $48.0M | $47.8M | $47.5M | $47.5M | $47.5M | $46.9M | $46.5M |
| Share buybacks | $596.3M | $72.2M | $229.8M | $7.20M | $0 | $250.0M | $250.1M | $250.7M |
From Zimmer Biomet's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Zimmer Biomet
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Source: Wikipedia — Zimmer Biomet
- Headquarters
- Warsaw, Indiana From SEC filings, Oct 2026
Recent News (15)
-
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind., Oct. 13, 2026 /PRNewswire/ -- Z…
-
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webc…
-
Is Zimmer Biomet Stock Underperforming the Nasdaq?
Is Zimmer Biomet Stock Underperforming the Nasdaq?
-
-
Zimmer Biomet declares $0.24 quarterly dividend
Zimmer Biomet declares $0.24 quarterly dividend
-
-
Are Wall Street Analysts Bullish on Zimmer Biomet Stock?
Are Wall Street Analysts Bullish on Zimmer Biomet Stock?
-
Zimmer Biomet Q2 Earnings Call Highlights Zimmer Biomet Q2 Earnings Call Highlights
-
Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary
-
Needham reiterates Hold on Zimmer Biomet stock after Q2 beat
Needham reiterates Hold on Zimmer Biomet stock after Q2 beat
-
Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook
-
Zimmer Biomet raises full-year outlook after second-quarter earnings beat Zimmer Biomet raises full-year outlook after second-quarter earnings beat
-
-
Earnings Preview: What To Expect From Zimmer Biomet’s Report Earnings Preview: What To Expect From Zimmer Biomet’s Report
-
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? Yahoo Finance
More Health Care stocks
- VRTX Vertex Pharmaceuticals
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services
- ZTS Zoetis
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories